Nan Shan Life Insurance Co. Ltd. Increases Position in Pfizer Inc. $PFE

Nan Shan Life Insurance Co. Ltd. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 7.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,306,108 shares of the biopharmaceutical company’s stock after purchasing an additional 235,799 shares during the period. Pfizer comprises approximately 2.6% of Nan Shan Life Insurance Co. Ltd.’s portfolio, making the stock its 11th largest position. Nan Shan Life Insurance Co. Ltd. owned approximately 0.06% of Pfizer worth $79,611,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Handelsbanken Fonder AB grew its holdings in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after purchasing an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. increased its position in Pfizer by 15.7% during the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after buying an additional 745,213 shares during the period. Leuthold Group LLC acquired a new position in Pfizer during the second quarter worth approximately $4,887,000. North Dakota State Investment Board purchased a new stake in Pfizer in the fourth quarter valued at approximately $5,348,000. Finally, Park National Corp OH boosted its holdings in shares of Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after acquiring an additional 186,053 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly results supported the move higher. Pfizer’s second-quarter earnings and revenue exceeded analyst expectations, while full-year 2026 EPS guidance remains $2.80–$3.00. The results suggest resilience despite comparisons with the prior year’s COVID-related performance. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Depo-Provera litigation uncertainty has been reduced. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging a connection between Depo-Provera and intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, the agreement removes a significant legal overhang. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Investors are focusing on oncology growth. Padcev, pipeline programs such as PF-08634404 and potential label expansions are central to Pfizer’s effort to offset declining COVID product sales and build longer-term growth. Pfizer’s Oncology Growth Push
• Positive Sentiment: Higher EPS estimates and dividend appeal may be supporting demand. Erste Group Bank increased its FY2026 EPS estimate, while Pfizer’s relatively high dividend yield may attract income-oriented investors seeking defensive healthcare exposure. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Analysts remain moderately optimistic, but Pfizer has underperformed the S&P 500 over the past year, underscoring continuing concerns about growth and execution. Is Pfizer Stock Underperforming the S&P 500?
• Negative Sentiment: Unusual options activity included purchases of 147,173 put options, about 24% above average. This may reflect bearish positioning or hedging and signals that some traders remain cautious despite the recent rally.

Pfizer Stock Up 0.4%

Shares of NYSE PFE opened at $28.57 on Wednesday. The firm’s 50-day moving average is $25.69 and its two-hundred day moving average is $26.31. The company has a market capitalization of $162.84 billion, a PE ratio of 37.59 and a beta of 0.34. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $29.09. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PFE shares. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Wolfe Research reiterated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Finally, Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.